22NW, LP
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), 22NW, LP reported 14 stock positions worth $104.7 million. Its top holding was Insperity (NSP) at 19.5% of the portfolio, followed by Nektar Therapeutics (NKTR, 18.7%) and Stoneridge (SRI, 17.3%). Compared with Q1 2026, it opened 1 new position, sold out of 3, added to 1 and reduced 1. The biggest buy was Core Molding Technologies (CMT, shares +23%) and the biggest sale an exit from Foster (lb) Class A (FSTR).
- Most Recent 13F
- Q2 2026
- Location
- SEATTLE, WA
- CIK
- 0001694297
- Portfolio Value
- $104.7M (Q2 2026)
- SEC Filing
- 0001214659-26-010406 ↗ filed Aug 14, 2026
Holdings Value
Holdings 14 stocks · $104.7M
| NSP Insperity Inc. | 19.45% | 493,000 | $20.4M | No change |
| NKTR Nektar Therapeutics | 18.75% | 281,115 | $19.6M | No change |
| SRI Stoneridge Inc. | 17.25% | 2,466,975 | $18.1M | No change |
| FOXF Fox Factory Holding Corp. | 10.98% | 678,165 | $11.5M | No change |
| CMT Core Molding Technologies Inc. | 6.17% | 273,521 | $6.5M | Add +22.8% |
| RGNX Regenxbio Inc. | 5.64% | 492,759 | $5.9M | No change |
| CULP Culp Inc. | 5.51% | 1,859,061 | $5.8M | No change |
| RZLT Rezolute Inc. | 4.08% | 820,653 | $4.3M | No change |
| UFI Unifi Inc. | 3.87% | 852,455 | $4.0M | No change |
| MLYS Mineralys Therapeutics Inc. | 2.93% | 113,840 | $3.1M | Reduce -74.4% |
| TISI Team Inc. | 2.81% | 170,187 | $2.9M | No change |
| ELDN Eledon Pharmaceuticals Inc. | 2.40% | 636,364 | $2.5M | No change |
| TBCH Turtle Beach Corp. | 0.17% | 14,430 | $180K | New |
| LFCR Lifecore Biomedical Inc. | 0.01% | 1,254 | $6K | No change |
Portfolio Sells Q1 2026 → Q2 2026
Portfolio Buys Q1 2026 → Q2 2026
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 14 | $104.7M | NSP, NKTR, SRI, FOXF, CMT |
| Q1 2026 | 16 | $145.9M | FSTR, NKTR, LFCR, NSP, MLYS |
| Q4 2025 | 20 | $237.6M | ANEB, FSTR, LFCR, NKTR, RGNX |
| Q3 2025 | 21 | $212.3M | ANEB, FSTR, LFCR, NKTR, SRI |
| Q2 2025 | 21 | $158.8M | FSTR, LFCR, ANEB, SRI, DHX |
| Q1 2025 | 20 | $149.1M | LFCR, FSTR, ANEB, STRL, CULP |
| Q4 2024 | 16 | $158.5M | FSTR, LFCR, ANEB, STRL, BBSI |
| Q3 2024 | 13 | $119.3M | FSTR, LFCR, STRL, CULP, ANEB |
| Q2 2024 | 13 | $117.2M | FSTR, LFCR, ANEB, STRL, BBSI |
| Q1 2024 | 13 | $116.1M | FSTR, ANEB, STRL, LFCR, BBSI |